RE:Edmonton Protocol Doing Their Own Thing ...
RichyRich:
From my research, I believe SVA are ahead of their competition:
1. Viacyte - are just starting early clinical trials.
Read; hsci.harvard.edu/news/stem-cells-billions-human-insulin-producing-cells
Read entire article, towards bottom particularly
SOME SCIENTISTS ARE CONVINCED THAT CELLS IN BAGS GOING TO BE THE
ANSWER TO TYPE 1 DIABETES -
Dr. Douglas MELTON, a Biolgoist at Harvard U, who has 2 children with type 1 diabetes
worries that the Viacyte system may not work. He thinks deposits of fibrotic, scarlike
tissue with glom onto the capsule stariving the cells inside of oxygen and blocking
their ability to sense sugar and release insulin. He says the "inefficiency" of the system
means the co would need a device about the size of a DVD to have enough
beta cells to effectively treat diabetes.
2. SEMMA - have a new stem cell technology but no device and no immune protection.
3. Thank you for introducing the name BETA LOGICS - a new co for me to research.
4. Re; Sertolin. My intuititon only - re Harvard, a golden opportunity for SVA,
we know the Cell Pouch is safe and biocompatible when placed in patients.
If Harvard prefer their strategy better than Sertolin, it is still a WIN WIN for Harvard
and SVA. We may have to give up Sertolin to get The Cell Pouch off and running.
To partner with Harvard is a real achievement. I believe at long last SVA is on
its way to becoming a success.